Transcatheter valve-in-valve implantation for failing bioprosthetic valves
被引:2
|
作者:
Azadani, Ali N.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Div Cardiothorac Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA
SFVAMC, San Francisco, CA USAUniv Calif San Francisco, Div Cardiothorac Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA
Azadani, Ali N.
[1
,2
]
Tseng, Elaine E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Div Cardiothorac Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA
SFVAMC, San Francisco, CA USAUniv Calif San Francisco, Div Cardiothorac Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA
Tseng, Elaine E.
[1
,2
]
机构:
[1] Univ Calif San Francisco, Div Cardiothorac Surg, Med Ctr, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA
Transcatheter valve implantation is becoming an alternative to conventional surgical valve replacement in patients at high surgical risk. While experience and acceptance with transcatheter techniques increased rapidly, transcatheter valve implantation within failing bioprostheses has emerged as a new concept (valve-in-valve implantation). Currently, the majority of prostheses implanted in patients are bioprosthetic valves that are expected to degenerate over time. Valve-in-valve implantation provides great utility in high-operative-risk patients since the mortality risk for reoperation can be significantly higher than for firsttime isolated valve replacement. Although two current devices are CE Mark approved in Europe for implantation within native valves, off-label clinical implementation of valve-in-valve have been described in numerous case reports. In this article, we provide an overview of transcatheter valve implantation in failing bioprostheses with an emphasis on the aortic position.